SOLIFENACIN TEVA 10 MG

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

SOLIFENACIN SUCCINATE

Disponible depuis:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Code ATC:

G04BD08

forme pharmaceutique:

TABLETS

Composition:

SOLIFENACIN SUCCINATE 10 MG

Mode d'administration:

PER OS

Type d'ordonnance:

Required

Fabriqué par:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Groupe thérapeutique:

SOLIFENACIN

Domaine thérapeutique:

SOLIFENACIN

indications thérapeutiques:

Solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Date de l'autorisation:

2018-06-30

Notice patient

PATIENT PACKAGE INSERT
IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS
)PREPARATIONS( - 1986
The medicine is dispensed with a
doctor’s prescription only
SOLIFENACIN TEVA
®
5 MG
TABLETS
COMPOSITION
Each tablet contains:
Solifenacin succinate 5 mg
SOLIFENACIN TEVA
®
10 MG
TABLETS
COMPOSITION
Each tablet contains:
Solifenacin succinate 10 mg
Inactive and allergenic ingredients in the
preparation - see section 2 “Important
information about some of the ingredients
of the medicine” and section 6 - “Further
Information”.
READ THE LEAFLET CAREFULLY IN ITS ENTIRETY
BEFORE USING THE MEDICINE. This leaflet
contains concise information about the
medicine. If you have further questions,
refer to the doctor or pharmacist.
THIS MEDICINE HAS BEEN PRESCRIBED
FOR THE TREATMENT OF YOUR AILMENT. DO
NOT PASS IT ON TO OTHERS. IT MAY HARM
THEM EVEN IF IT SEEMS TO YOU THAT THEIR
AILMENT/MEDICAL CONDITION IS SIMILAR.
Do not use the medicine in children and
adolescents under the age of 18.
1. WHAT IS THE MEDICINE INTENDED
FOR?
The medicine is intended for the
treatment
of
urinary
incontinence
and/or conditions of increased urinary
frequency and urgency in patients with
an overactive bladder.
THERAPEUTIC GROUP: Anticholinergics
2. BEFORE USING THE MEDICINE
DO NOT USE THE MEDICINE:
• If you are sensitive )allergic( to
solifenacin or to any of the additional
ingredients
contained
in
the
medicine.
• In case of urinary retention, severe
disorders of the digestive system
)toxic megacolon(, myasthenia
gravis )extreme muscle weakness(,
intraocular pressure, accompanied
by decreased vision )glaucoma(.
• In patients undergoing kidney dialysis
and in patients with severe liver
insufficiency.
• In patients with severe kidney disease
or with moderate liver disease, who
are being concomitantly treated with
another medicine that reduces the
clearance of solifenacin from the
body, such as ketoconazole.
SPECIAL WARNINGS REGARDING USE OF
THE MEDICINE
BEFORE BEGINNING TREATMENT WITH
SOLIFENACIN TEVA, TELL THE DOCTOR IF:
You have a pro